Merck, which at last count faced 23,800 lawsuits from Vioxx users, is scheduled to go to trial in two separate cases next week—one a federal case in New Orleans, the other a lawsuit in a California state court in Los Angeles involving two former Vioxx users.
Two more trials are scheduled to begin in late November, a state court case in Alabama and another federal case to be heard in New Orleans.
Also looming is a January trial in New Jersey in which as many as eight Vioxx cases could be tried at the same time, though Merck objects to the grouping of the cases together and has asked a judge to reconsider.
In that case, Merck again will face off against high-profile plaintiffs' lawyer Mark Lanier (pic), who last year won a $253 million verdict—the biggest verdict a plaintiff has won in Vioxx litigation so far.
Source
Two more trials are scheduled to begin in late November, a state court case in Alabama and another federal case to be heard in New Orleans.
Also looming is a January trial in New Jersey in which as many as eight Vioxx cases could be tried at the same time, though Merck objects to the grouping of the cases together and has asked a judge to reconsider.
In that case, Merck again will face off against high-profile plaintiffs' lawyer Mark Lanier (pic), who last year won a $253 million verdict—the biggest verdict a plaintiff has won in Vioxx litigation so far.
Source
No comments:
Post a Comment